SavedAdd your journal

Journals / Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2021 / Cilt: 8 - Sayı: 1

Potential Interactions between Increased Cytokines in COVID-19 and Drugs Used to Treat COVID-19

COVİD-19 da Sitokinler ve COVİD- 19 Tedavisinde Kullanılan İlaçlar Arasında Potansiyel İlaç Etkileşimleri

Yeşim TUNÇOK
Tülün ÖZTÜRK
Tuğba GÜRPINAR
Canet İNCİR BALABAN
Pages
174–185
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on the knowledge of cytokine-drug interactions occurring in the infection andinflammation stage, the aim of this review was to ascertain the influence of uncontrolled cytokine release on themetabolism of drugs used alone or in combination to treat COVID-19 patients and predict drug-drug interactionscausing adverse effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:During COVID-19 infection, virus and host cell interactions lead to the acute production of very strong immunemediators.
📊
Key Findings & Data:Under infectious and inflammatoryconditions, clinical and experimental studies have demonstrated that hepatic and extrahepatic cytochrome P450 (CYP)enzymes and carrier proteins responsible for drug metabolism are specifically regulated by many cytokines.Downregulation of these enzymes by cytokines can cause an elevation in plasma drug levels and/or lead to adversedrug reactions and/or toxicity.
💡
Conclusion & Impact:Based on the knowledge of cytokine-drug interactions occurring in the infection andinflammation stage, the aim of this review was to ascertain the influence of uncontrolled cytokine release on themetabolism of drugs used alone or in combination to treat COVID-19 patients and predict drug-drug interactionscausing adverse effects.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

During COVID-19 infection, virus and host cell interactions lead to the acute production of very strong immunemediators. The clinical status caused by damage throughout the body is mostly due to excessive pro-inflammatorycytokine production from virus-induced macrophages and granulocytes. Under infectious and inflammatoryconditions, clinical and experimental studies have demonstrated that hepatic and extrahepatic cytochrome P450 (CYP)enzymes and carrier proteins responsible for drug metabolism are specifically regulated by many cytokines.Downregulation of these enzymes by cytokines can cause an elevation in plasma drug levels and/or lead to adversedrug reactions and/or toxicity. Based on the knowledge of cytokine-drug interactions occurring in the infection andinflammation stage, the aim of this review was to ascertain the influence of uncontrolled cytokine release on themetabolism of drugs used alone or in combination to treat COVID-19 patients and predict drug-drug interactionscausing adverse effects.

Özet

COVID-19 enfeksiyonu sırasında virus ve konakçı hücre etkileşimleri çok güçlü immun mediyatörlerin akut üretimine yol açmaktadır. Ağır klinik durum çoğunlukla virüsün indüklediği makrofaj ve granülositlerden aşırı inflammatuar sitokin üretimine bağlıdır. Enfeksiyöz ve inflammatuar koşullar altında, klinik ve deneysel çalışmalar göstermiştir ki, ilaç metabolizmasından sorumlu olan karaciğer ve karaciğer dışı sitokrom P450 (CYP) enzimleri ve taşıyıcı proteinler pek çok sitokinler tarafından spesifik olarak regüle edilmektedirler. Sitokinler tarafından bu enzimlerin downregülasyonu, plazma ilaç düzeylerinde yükselmeye neden olabilir ve/veya advers ilaç reaksiyonlarına ve/veya toksisiteye yol açabilir. İnfeksiyon ve inflammasyon koşullarında oluşan sitokin-ilaç etkileşimleri bilgilerimiz temelinde, bu derlemenin amacı, COVID-19 hastalarını tedavi etmek için tek başına veya kombinasyonla kullanılan ilaçların metabolizmaları üzerine kontrolsüz sitokin salınımının etkisini araştırmak ve advers ilaç etkilerine neden olabilecek ilaç- ilaç etkileşimlerini öngörmektir.

🔖

Cite This Article

TUNÇOK, Y., ÖZTÜRK, T., GÜRPINAR, T., BALABAN, C. İ. (2022). Potential Interactions between Increased Cytokines in COVID-19 and Drugs Used to Treat COVID-19. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Cilt: 8 - Sayı: 1, 174–185. https://ajindex.com/articles/472691

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. World Health Organization (2020). Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus- 2019/technical-guidance/naming-the-coronavirus-disease-(covid- 2019)-and-the-virus-that-causes-it (accessed 21 January 2021)
  2. Prajapat, M, Sarma, P, Shekhar, N, et al. Drug targets for corona virus: A systematic review, Indian Journal of Pharmacology 2020; 52: 56–65
  3. Kazak, A, Hintistan, S, Önal, B. COVID-19 Vaccine Development Studies in the World and Turkey, Celal Bayar University-Health Sciences Institute Journal, 2020, 7, 571-575
  4. Wang, F, Nie, J, Wang, H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia, The Journal of Infectious Diseases, 2020, 221; 1762-1769
  5. Mehta, P, McAuley, D, F, Brown, M, Sanchez, E, Tattersall, R, S, Manson, J, J, H, L, H, Acros Speciality Collaboration, COVID-19: consider cytokine storm syndromes and İmmunosuppression, The Lancet, 2020, 395, 1034-1035
  6. Li, G, Fan, Y, Lai, Y, et al. Coronavirus infections and immune responses, Journal of Medical Viroogy, 2020, 92, 424-432
  7. Mc Gonagle, D, Sharif, K, O’Regan, A, Brigewood, C, Interleukin- 6 use in COVID-19 pneumonia related macrophage activation syndrome, Autoimmunity Reviews, 2020: 19, 102537
  8. Sen, E, S, Ramanan, A, V, Cytokine Storm Syndrome Associated with Hemorrhagic Fever and Other Viruses, in: R, O, Cron, E, M, Behrens, (Eds), Cytokine Storm Syndrome. Springer Nature Switzerland AG, 2019, 277-298
  9. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet London England, 2020, 395, 497-506
  10. Li, H, Xiang, X, Ren, H, et al. Serum Amyloid A is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19), The Journal of Infection, 2020, 80, 646-655
  11. Stavropoulou, E, Pircalabioru, G, G, Bezirtzoglou, E. The Role of Cytochromes P450 in infection, Frontiers in Immunology, 2018, 31, 89
  12. Goralski, K, B, Ladda, A, M, O McNeil, J, Drug-Cytokine Interactions, in: Georgiev V, Pai MP, Kiser, J.J, Gubbins, P.O and Rodvold, K.A (Eds), Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions, Switzerland, Springer International Publishing, 2018, 163-204
  13. Morgan, E, T, Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clinical Pharmacology and Therapeutics, 2009,